2021 Updates: Lilly's Global COVID-19 Response

Eli Lilly and Company  | March 2, 2021

NOTE: For more information about Lilly's COVID-19 therapies authorized for emergency use, contact the Lilly COVID Hotline at 1-855-LillyC19 (1-855-545-5921).

Lilly continues to closely monitor the COVID-19 pandemic and its global impact. As this is an evolving topic, Lilly will include relevant announcements and information on this page.

On COVID-19 and Clinical Trials:

  • If you are a clinical investigator, or you represent a hospital or clinical site, and are interested in participating as an investigator or site in one of Lilly’s clinical trials for a potential COVID-19 treatment, call 1-877-CT-LILLY (1-877-285-4559) or email covid19potentialsite@lilly.com.

  • Patients interested in participating in one of our clinical trials for a potential COVID-19 treatment should visit Lilly TrialGuide for information regarding eligibility for ongoing trials.

Here’s what we’re doing to ensure people have access to Lilly medicines:

News Releases, Resources and Multimedia

March

February

January

All-Updates Timeline

March 2, 2021

Today we published a COVID-19 antibody allocation and transparency tracker. Lilly is working with global regulators to make our neutralizing antibody available for emergency use in countries around the world.

February 26, 2021

Lilly announced an agreement with the U.S. government to provide a minimum of 100,000 doses of our investigational neutralizing antibodies administered together for the treatment of mild to moderate COVID19 in high-risk patients.

February 9, 2021

Today we announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for investigational bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together. This therapy is authorized for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization.

January 28, 2021

Lilly is partnering with Indiana health systems to launch pilot infusion center locations serving central, northern, and now southern parts of the state. These are intended to provide Hoosiers with access to important COVID-19 treatments. Multiple neutralizing antibody therapies have been granted Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in high-risk patients.

Additionally, Lilly has published an operations guide about infusion units for COVID-19 antibody treatment and COVID antibody infusion clinic learnings.

January 27, 2021

Lilly, Vir Biotechnology and GlaxoSmithKline (GSK) announced a collaboration to evaluate a combination of two therapies in low-risk patients with mild to moderate COVID-19. This unique collaboration, combining monoclonal antibodies from separate companies, is designed to explore whether clinical outcomes can be further improved.

January 26, 2021

Lilly shared today that new Phase 3 trial data show our neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together significantly reduced COVID-19-related hospitalizations and deaths in high-risk patients recently diagnosed with COVID-19.

January 21, 2021

Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Lilly announced today. The BLAZE-2 COVID-19 prevention trial – conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the COVID-19 Prevention Network (CoVPN) – enrolled residents and staff at skilled nursing and assisted living facilities, commonly referred to as nursing homes, across the U.S.

Patients and physicians can visit covid.infusioncenter.org or the HHS Therapeutics Distribution locator to find a potential treatment location near you.

January 15, 2021

If a high-risk patient tests positive for COVID-19 and has mild-to-moderate symptoms, new monoclonal antibody treatments could provide real help – not just hope. To learn more, visit combatcovid.hhs.gov.

2020 Highlights

Learn more about Lilly's 2020 efforts to fight COVID-19.

Note: The FDA grants Emergency Use Authorization to provide availability of a medicine that may help diagnose, treat or prevent a life-threatening disease when no adequate and approved alternatives are available.